X
[{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche experimental drug flops in early Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Terminates Dipraglurant Phase 2b\/3 Study in Patients with Dyskinesia Associated with Parkinson\u2019s Disease due to Slow Recruitment Rate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Addex Therapeutics"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund LTV","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Raises $4.2 Million in Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Addex Therapeutics"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund Ltd.","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Completes $4.2 Million Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Addex Therapeutics"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Noema Pharma"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma Receives FDA Fast Track Designation for Basimglurant (NOE-101) in Trigeminal Neuralgia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Noema Pharma"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Noema Pharma"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Addex Therapeutics"}]
Find Neurology Drugs in Phase II/III Clinical Development in SWITZERLAND
Filters
Details:
Following oral administration, ADX48621 (dipraglurant) was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models.
Lead Product(s):
Dipraglurant
Therapeutic Area: Neurology
Product Name: ADX48621
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 04, 2023
Details:
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and seizures in TSC.
Lead Product(s):
Basimglurant
Therapeutic Area: Neurology
Product Name: NOE-101
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Forbion
Deal Size: $112.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
March 07, 2023
Details:
Basimglurant (NOE-101) is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) for the treatment of trigeminal neuralgia (TN).
Lead Product(s):
Basimglurant
Therapeutic Area: Neurology
Product Name: NOE-101
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 18, 2022
Details:
NOE-101 (basimglurant), a highly selective, potent, and cell-penetrant negative allosteric modulator of mGlu5 receptors for the management of pain associated with TN.
Lead Product(s):
Basimglurant
Therapeutic Area: Neurology
Product Name: NOE-101
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 06, 2022
Details:
Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Lead Product(s):
Dipraglurant
Therapeutic Area: Neurology
Product Name: ADX48621
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Armistice Master Fund Ltd.
Deal Size: $4.2 million
Upfront Cash: Undisclosed
Deal Type: Financing
July 26, 2022
Details:
Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Lead Product(s):
Dipraglurant
Therapeutic Area: Neurology
Product Name: ADX48621
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Armistice Master Fund LTV
Deal Size: $4.2 million
Upfront Cash: Undisclosed
Deal Type: Financing
July 22, 2022
Details:
ADX48621 (Dipraglurant (Immediate Release), as a novel orally available mGlu5 NAM, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Lead Product(s):
Dipraglurant
Therapeutic Area: Neurology
Product Name: ADX48621
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 17, 2022
Details:
Gantenerumab, did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease.
Lead Product(s):
Gantenerumab
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 10, 2020
Details:
Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA
Lead Product(s):
Risdiplam
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 23, 2020